查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1802942

2032 年端粒基因治疗市场预测：按治疗类型、给药方式、发展阶段、载体类型、疾病适应症、应用、最终用户和地区进行的全球分析

Telomere Gene Therapy Market Forecasts to 2032 - Global Analysis By Therapy Type, Delivery Method, Development Stage, Vector Type, Disease Indication, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球端粒基因治疗市场预计在 2025 年价值 6,075 万美元，预计到 2032 年将达到 2.3745 亿美元，预测期内的复合年增长率为 21.5%。

端粒基因疗法是再生医学的新兴领域，致力于延长或恢復端粒——染色体末端的保护帽，它会随着细胞分裂和衰老而缩短。细胞老化、老龄化和老龄化相关疾病都与端粒缩短密切相关。透过利用基因治疗技术活化端粒酶（一种保存和延长端粒的酶），科学家希望能够使细胞恢復活力，增强组织功能，并可能推迟退化性疾病的发生。虽然安全性问题（包括不受控制的细胞增殖和致癌可能性）仍然是主要障碍，但早期在动物模型上的研究已显示出令人鼓舞的结果，包括寿命和健康寿命的延长。

《欧洲分子医学组织》（EMBO Molecular Medicine）发表的一项研究发现，端粒酶基因治疗使小鼠的平均寿命延长了24%，且癌症发生率没有增加。接受治疗的小鼠也表现出组织再生能力增强，老化标记减少。

遗传和老龄化相关疾病的发生率不断上升

推动端粒基因治疗市场发展的主要因素之一是与老龄化相关的遗传性疾病的日益增多。端粒缩短与阿兹海默症和心血管疾病等退化性疾病一样，也是特发性肺纤维化、再次障碍性贫血和骨髓发育不良症候群等疾病的关键因素。随着人口老化，针对细胞衰退根本原因的治疗需求显着增加。早期诊断、生物标记识别和基因检测的进展也增加了符合创新疗法条件的患者数量。此外，随着全球慢性病发病率的上升，以端粒为重点的干预措施被视为减缓疾病进展和改善生活品质的一种颇具吸引力的选择。

增加罹癌的风险

端粒基因治疗发展面临的最大障碍之一是细胞增殖失控的风险增加，可能导致癌症。由于大多数成年体细胞会自然抑制端粒酶活性，人工重新重新运作该活性可能会促进恶性转化。临床应用必须严格控制，以防止癌前细胞永生化。这种风险会增加监管审查，使治疗设计复杂化，并延缓开发进度。安全性问题，尤其是在抗衰老和预防应用方面，限制了患者的接受度，并引发了伦理争议。因此，致癌性仍然是阻碍端粒疗法广泛应用的最大生物学和经济障碍。

长寿医学和抗衰老医学的增长

长寿和抗衰老龄化医学领域的快速发展为端粒基因疗法提供了最光明的前景之一。老化的主要征兆之一是端粒缩短，而延长端粒的治疗可以延长寿命，甚至延缓与老龄化相关的衰老。随着世界各地人们寿命的延长，对不仅能治疗疾病还能保持活力的解决方案的需求也日益增长。透过吸引健康产业、私人长寿诊所和消费者导向的生技公司，端粒疗法有望从疾病管理扩展到预防性医疗保健。

来自替代医学的竞争

来自替代疗法的竞争，例如干细胞疗法、抗衰老药物、基于CRISPR的基因组编辑以及改变mTOR、NAD+和sirtuins等衰老通路的小分子药物，对端粒基因治疗构成了重大威胁。与基于端粒的干预措施相比，这些治疗方法的製造成本更低、安全隐患更少，并且经常通过临床试验。如果这些竞争技术被证明能够成功治疗退化性疾病或延长寿命，端粒疗法可能很难出现。儘管端粒疗法具有生物学潜力，但投资者和医疗保健提供者可能更倾向于更安全、更成熟的替代技术。

COVID-19的影响：

端粒基因治疗市场在许多方面受到了 COVID-19 疫情的影响。一方面，全球资金筹措週期、供应链和临床试验的中断暂时减缓了研究进度，并推迟了几种实验性治疗方法的开发时间表。然而，疫情也增加了人们对基于基因的解决方案的兴趣，因为病毒载体平台和 mRNA 疫苗迅速证明了其扩充性和安全性。先进的递送系统的检验增强了对基因介入的投资和监管信心，间接使端粒相关研究受益。此外，鑑于 COVID-19 的长期健康影响，例如某些患者的免疫功能障碍和生物老化加速，端粒标靶治疗至关重要。

端粒酶活化疗法预计将成为预测期内最大的治疗领域

端粒酶激活疗法预计将在预测期内占据最大的市场占有率，因为其主要目标是改善或重新运作端粒酶——一种维持和延长端粒的酶。此策略透过逆转端粒缩短直接解决了细胞老化的基本过程之一，使其在治疗和预防方面都极具吸引力。临床研究和营养补充剂（例如端粒酶激活剂）已证明对端粒长度和免疫功能具有可量化的影响，进一步激发了人们的兴趣。端粒酶活化疗法是市场上商业性程度最高、科学检验最充分的领域，其发展受到长寿医学、抗衰老研究和再生医疗领域强劲需求的推动。

腺结合病毒(AAV) 部分预计将在预测期内实现最高复合年增长率

腺结合病毒(AAV) 领域预计将在预测期内呈现最高成长率。这得益于其良好的安全记录、能够长时间产生基因表现以及引发免疫反应的风险相对较低。许多人认为 AAV 载体是递送遗传物质最可靠的方法，尤其适用于需要长期疗效的老龄化性疾病和慢性疾病的治疗。 AAV 载体核准罕见疾病基因治疗的成功，进一步增强了人们对使用 AAV 载体进行端粒干预的信心。

比最大的地区

预计北美将在预测期内占据最大的市场占有率。该地区拥有强大的生物技术部门、先进的医疗保健系统以及对基因和抗衰老研究的大量投资。由于大量的临床试验、已建立的监管途径（如 FDA RMAT 指定）以及处于端粒疗法前沿的关键生物技术公司和新兴企业的存在，美国在该领域处于全球市场领先地位。大量创业投资资金筹措、产学合作以及最尖端科技的早期采用进一步加强了该地区的主导地位。此外，由于对癌症和与老龄化相关的疾病的最先进治疗疗法的需求不断增长，北美将继续在全球占据最大市场占有率。

复合年增长率最高的地区：

受人口老化、医疗成本上涨以及政府对生物技术研究的大力资助推动，预计亚太地区在预测期内将呈现最高的复合年增长率。再生医学和基因疗法正吸引来自中国、日本和韩国等国的大量投资。国内生物技术公司与国际公司之间的临床试验和合作也不断增加。随着医疗基础设施的改善和人们对长寿科学认知的不断提高，端粒相关创新的有利环境正在形成。此外，亚太地区经济高效的生产能力和令人鼓舞的监管变化也加速了相关技术的采用，使亚太地区成为成长最快的市场领域。

免费客製化服务

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 二手研究资料
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球端粒基因治疗市场（依治疗类型）

  • 端粒酶活化治疗
  • 端粒延长疗法
  • 端粒保护疗法

6. 全球端粒基因治疗市场（以递送方式）

  • 病毒载体
  • 非病毒方法
  • 体外受精
  • 体内递送

7. 全球端粒基因治疗市场（依发展阶段）

  • 临床前
  • 临床试验（I期）
  • 临床试验（II期）
  • 临床试验（III期）
  • 核准的治疗方法
  • 管道候选人

8. 全球端粒基因治疗市场（依载体型）

  • 腺结合病毒（AAV）
  • 慢病毒
  • 逆转录病毒
  • 腺病毒
  • 其他向量类型

9. 全球端粒基因治疗市场（依疾病适应症）

  • 特发性肺纤维化
  • 再生障碍性贫血
  • 癌症亚型
  • 罕见端粒疾病

第 10 章全球端粒基因治疗市场（按应用）

  • 抗老和长寿
  • 肿瘤学
  • 遗传性疾病
  • 再生医学

第 11 章全球端粒基因治疗市场（按最终用户）

  • 医院和诊所
  • 研究与机构
  • 生物技术和製药公司

12. 全球端粒基因治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十三章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十四章 公司概况

  • Geron Corporation
  • AgeX Therapeutics
  • Turn Biotechnologies
  • Calico Life Sciences
  • Juvenescence Ltd
  • Sierra Sciences
  • Telomere Therapeutics
  • Altos Labs Inc
  • BioViva Sciences
  • Retro Biosciences
  • Telocyte
  • Elixirgen Therapeutics
Product Code: SMRC30468

According to Stratistics MRC, the Global Telomere Gene Therapy Market is accounted for $60.75 million in 2025 and is expected to reach $237.45 million by 2032 growing at a CAGR of 21.5% during the forecast period. Telomere gene therapy is an emerging field of regenerative medicine that focuses on extending or restoring telomeres-the protective caps at the ends of chromosomes that shorten as cells divide and age. Cellular senescence, aging, and age-related disorders are all strongly associated with telomere shortening. Scientists hope to revitalize cells, enhance tissue function, and possibly postpone the onset of degenerative diseases by employing gene therapy techniques to activate telomerase, the enzyme that preserves and lengthens telomeres. Although safety issues, such as the possibility of unchecked cell growth and cancer, continue to be significant obstacles, early research in animal models has produced encouraging results, such as an extended lifespan and health span.

According to a study published in EMBO Molecular Medicine, data shows that telomerase gene therapy in mice extended their median lifespan by 24% without increasing cancer incidence. Treated mice showed improved tissue regeneration and reduced markers of aging.

Market Dynamics:

Driver:

Increasing frequencies of genetic and age-related disorders

One of the main factors propelling the telomere gene therapy market is the growing prevalence of age-related and genetic illnesses. Along with degenerative diseases like Alzheimer's and cardiovascular disease, telomere shortening is a key factor in diseases likes idiopathic pulmonary fibrosis, aplastic anemia, and myelodysplastic syndromes. The need for treatments that target the underlying causes of cellular decline rises significantly as populations age. The number of patients eligible for innovative treatments is also growing as a result of advancements in early diagnostics, biomarker identification, and genetic testing. Additionally, telomere-focused interventions are positioned as appealing choices to slow disease progression and enhance quality of life as the incidence of chronic diseases rises worldwide.

Restraint:

Elevated oncogenesis risk

The increased risk of causing unchecked cell growth, which can result in cancer, is one of the most significant barriers to the development of telomere gene therapy. The majority of adult somatic cells naturally suppress telomerase activity, so reactivating it artificially runs the risk of facilitating malignant transformation. To prevent precancerous cells from becoming immortal, clinical translation needs to be carefully controlled. This risk slows development timelines by increasing regulatory scrutiny and complicating therapy design. Safety issues restrict patient acceptance and spark ethical discussions, especially when it comes to anti-aging or preventive applications. As a result, the biggest biological and financial obstacle to the widespread use of telomere therapy is still oncogenesis.

Opportunity:

Growth into longevity and anti-aging medicine

The quickly expanding fields of longevity and anti-aging medicine present one of the most promising prospects for telomere gene therapy. One of the main signs of aging is telomere shortening; treatments that lengthen telomeres may prolong life and even postpone age-related decline. The demand for solutions that not only treat illness but also maintain vitality is rising as people around the world live longer. By attracting wellness sectors, private longevity clinics, and consumer-focused biotech companies, telomere therapy may expand beyond disease management into preventive healthcare.

Threat:

Competition from alternative medical practices

The competition from alternative therapeutic approaches, such as stem cell therapy, senolytics, CRISPR-based genome editing, and small-molecule medications that alter aging pathways like mTOR, NAD+, or sirtuins, is a significant threat to telomere gene therapy. Compared to telomere-based interventions, these therapies may be less expensive to produce, have fewer safety concerns, and are frequently more advanced in clinical trials. Telomere therapies might find it difficult to stand out if these rival technologies are successful in treating degenerative diseases or prolonging life expectancy. Despite telomere therapy's biological potential, investors and healthcare providers may favor safer, more thoroughly proven alternatives, which would slow adoption and confine it to a specialized role.

Covid-19 Impact:

The market for telomere gene therapy experienced mixed effects from the COVID-19 pandemic. On the one hand, worldwide disruptions in funding cycles, supply chains, and clinical trials momentarily slowed down research, causing several experimental therapies' development timelines to be delayed. However, the pandemic also increased interest in gene-based solutions because viral vector platforms and mRNA vaccines quickly demonstrated their scalability and safety. The validation of sophisticated delivery systems increased investment and regulatory confidence in genetic interventions, which indirectly benefited telomere-focused research. Moreover, telomere-targeted treatments are also important because of the long-term health effects of COVID-19, which include immunological dysfunction and accelerated biological aging in certain patients.

The telomerase activation therapy segment is expected to be the largest during the forecast period

The telomerase activation therapy segment is expected to account for the largest market share during the forecast period because its main goal is to improve or reactivate telomerase, the enzyme that keeps and lengthens telomeres. This strategy directly addresses one of the fundamental processes of cellular aging by reversing telomere shortening, which makes it very appealing for both therapeutic and preventive uses. Interest has been further stoked by clinical research and nutraceutical products that demonstrate quantifiable effects on telomere length and immune function, such as telomerase activators. As the most commercially advanced and scientifically validated segment of the market, telomerase activation therapy leads due to strong demand from longevity medicine, anti-aging research, and regenerative healthcare.

The adeno-associated virus (AAV) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the adeno-associated virus (AAV) segment is predicted to witness the highest growth rate, motivated by its good safety record, capacity to produce gene expression over an extended period of time, and comparatively low risk of inciting immunological reactions. Many people believe that AAV vectors are the most dependable way to deliver genetic material, particularly in treatments for age-related and chronic illnesses where long-lasting effects are needed. Confidence in their application for telomere-based interventions has been further increased by their demonstrated success in approved gene therapies for rare diseases.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, bolstered by its robust biotechnology sector, sophisticated healthcare system, and substantial investment in genetic and anti-aging research. With a large number of clinical trials, well-established regulatory pathways such as the FDA's RMAT designation, and the presence of significant biotech companies and startups at the forefront of telomere-focused therapies, the United States leads the world in this area. The region's dominance is further strengthened by substantial venture capital funding, industry-academia partnerships, and early adoption of cutting-edge technologies. Furthermore, North America continues to hold the biggest market share in the world due to rising demand for cutting-edge treatments that target cancer and age-related illnesses.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, propelled by its aging population, growing healthcare costs, and robust government funding for biotechnology research. Regenerative medicine and gene therapy are receiving significant investments from nations like China, Japan, and South Korea. There are also more clinical trials and collaborations between domestic biotech companies and international players. An environment that is conducive to telomere-based innovations is being created by the growing healthcare infrastructure and increased awareness of longevity science. Moreover, the region's cost-effective manufacturing capabilities and encouraging regulatory changes are also speeding up adoption, making Asia-Pacific the market segment with the fastest rate of growth.

Key players in the market

Some of the key players in Telomere Gene Therapy Market include Geron Corporation, AgeX Therapeutics, Turn Biotechnologies, Calico Life Sciences, Juvenescence Ltd, Sierra Sciences, Telomere Therapeutics, Altos Labs Inc, BioViva Sciences, Retro Biosciences, Telocyte and Elixirgen Therapeutics.

Key Developments:

In June 2025, Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell for investigational therapies aimed at interleukin-11 (IL-11), including a Phase I-stage monoclonal antibody targeting age-related conditions. Under the deal, Calico is paying $25 million upfront to gain global rights-excluding greater China-to 9MW3811, the lead IL-11 candidate. The agreement could eventually reach $571 million, tied to development and commercial milestones.

In November 2024, Geron Corporation has announced a $375 million financing agreement aimed at supporting the commercial rollout of Rytelo. The money, which will also be used to advance the firm's pipeline, comprises $250 million in debt from funds managed by Pharmakon Advisors and a $125 million synthetic royalty agreement with Royalty Pharma.

In May 2024, Turn Biotechnologies announced an exclusive global licensing agreement with pharmaceutical manufacturer HanAll Biopharma to develop groundbreaking medicines for the treatment of age-related eye and ear conditions. The agreement, potentially exceeding $300 million in value for the first of multiple planned products, significantly expands the relationship between the companies. HanAll originally invested in Turn Bio in 2022.

Therapy Types Covered:

  • Telomerase Activation Therapy
  • Telomere Lengthening Therapy
  • Telomere Protection Therapy

Delivery Methods Covered:

  • Viral Vectors
  • Non-Viral Methods
  • Ex Vivo Delivery
  • In Vivo Delivery

Development Stages Covered:

  • Preclinical
  • Clinical Trials (Phase I)
  • Clinical Trials (Phase II)
  • Clinical Trials (Phase III)
  • Approved Therapies
  • Pipeline Candidates

Vector Types Covered:

  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Retrovirus
  • Adenovirus
  • Other Vector Types

Disease Indications Covered:

  • Idiopathic Pulmonary Fibrosis
  • Aplastic Anemia
  • Cancer Subtypes
  • Rare Telomere Disorders

Applications Covered:

  • Anti-Aging & Longevity
  • Oncology
  • Genetic Disorders
  • Regenerative Medicine

End Users Covered:

  • Hospitals & Clinics
  • Research Institutes
  • Biotech & Pharmaceutical Companies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Telomere Gene Therapy Market, By Therapy Type

  • 5.1 Introduction
  • 5.2 Telomerase Activation Therapy
  • 5.3 Telomere Lengthening Therapy
  • 5.4 Telomere Protection Therapy

6 Global Telomere Gene Therapy Market, By Delivery Method

  • 6.1 Introduction
  • 6.2 Viral Vectors
  • 6.3 Non-Viral Methods
  • 6.4 Ex Vivo Delivery
  • 6.5 In Vivo Delivery

7 Global Telomere Gene Therapy Market, By Development Stage

  • 7.1 Introduction
  • 7.2 Preclinical
  • 7.3 Clinical Trials (Phase I)
  • 7.4 Clinical Trials (Phase II)
  • 7.5 Clinical Trials (Phase III)
  • 7.6 Approved Therapies
  • 7.7 Pipeline Candidates

8 Global Telomere Gene Therapy Market, By Vector Type

  • 8.1 Introduction
  • 8.2 Adeno-Associated Virus (AAV)
  • 8.3 Lentivirus
  • 8.4 Retrovirus
  • 8.5 Adenovirus
  • 8.6 Other Vector Types

9 Global Telomere Gene Therapy Market, By Disease Indication

  • 9.1 Introduction
  • 9.2 Idiopathic Pulmonary Fibrosis
  • 9.3 Aplastic Anemia
  • 9.4 Cancer Subtypes
  • 9.5 Rare Telomere Disorders

10 Global Telomere Gene Therapy Market, By Application

  • 10.1 Introduction
  • 10.2 Anti-Aging & Longevity
  • 10.3 Oncology
  • 10.4 Genetic Disorders
  • 10.5 Regenerative Medicine

11 Global Telomere Gene Therapy Market, By End User

  • 11.1 Introduction
  • 11.2 Hospitals & Clinics
  • 11.3 Research Institutes
  • 11.4 Biotech & Pharmaceutical Companies

12 Global Telomere Gene Therapy Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Geron Corporation
  • 14.2 AgeX Therapeutics
  • 14.3 Turn Biotechnologies
  • 14.4 Calico Life Sciences
  • 14.5 Juvenescence Ltd
  • 14.6 Sierra Sciences
  • 14.7 Telomere Therapeutics
  • 14.8 Altos Labs Inc
  • 14.9 BioViva Sciences
  • 14.10 Retro Biosciences
  • 14.11 Telocyte
  • 14.12 Elixirgen Therapeutics

List of Tables

  • Table 1 Global Telomere Gene Therapy Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Telomere Gene Therapy Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 3 Global Telomere Gene Therapy Market Outlook, By Telomerase Activation Therapy (2024-2032) ($MN)
  • Table 4 Global Telomere Gene Therapy Market Outlook, By Telomere Lengthening Therapy (2024-2032) ($MN)
  • Table 5 Global Telomere Gene Therapy Market Outlook, By Telomere Protection Therapy (2024-2032) ($MN)
  • Table 6 Global Telomere Gene Therapy Market Outlook, By Delivery Method (2024-2032) ($MN)
  • Table 7 Global Telomere Gene Therapy Market Outlook, By Viral Vectors (2024-2032) ($MN)
  • Table 8 Global Telomere Gene Therapy Market Outlook, By Non-Viral Methods (2024-2032) ($MN)
  • Table 9 Global Telomere Gene Therapy Market Outlook, By Ex Vivo Delivery (2024-2032) ($MN)
  • Table 10 Global Telomere Gene Therapy Market Outlook, By In Vivo Delivery (2024-2032) ($MN)
  • Table 11 Global Telomere Gene Therapy Market Outlook, By Development Stage (2024-2032) ($MN)
  • Table 12 Global Telomere Gene Therapy Market Outlook, By Preclinical (2024-2032) ($MN)
  • Table 13 Global Telomere Gene Therapy Market Outlook, By Clinical Trials (Phase I) (2024-2032) ($MN)
  • Table 14 Global Telomere Gene Therapy Market Outlook, By Clinical Trials (Phase II) (2024-2032) ($MN)
  • Table 15 Global Telomere Gene Therapy Market Outlook, By Clinical Trials (Phase III) (2024-2032) ($MN)
  • Table 16 Global Telomere Gene Therapy Market Outlook, By Approved Therapies (2024-2032) ($MN)
  • Table 17 Global Telomere Gene Therapy Market Outlook, By Pipeline Candidates (2024-2032) ($MN)
  • Table 18 Global Telomere Gene Therapy Market Outlook, By Vector Type (2024-2032) ($MN)
  • Table 19 Global Telomere Gene Therapy Market Outlook, By Adeno-Associated Virus (AAV) (2024-2032) ($MN)
  • Table 20 Global Telomere Gene Therapy Market Outlook, By Lentivirus (2024-2032) ($MN)
  • Table 21 Global Telomere Gene Therapy Market Outlook, By Retrovirus (2024-2032) ($MN)
  • Table 22 Global Telomere Gene Therapy Market Outlook, By Adenovirus (2024-2032) ($MN)
  • Table 23 Global Telomere Gene Therapy Market Outlook, By Other Vector Types (2024-2032) ($MN)
  • Table 24 Global Telomere Gene Therapy Market Outlook, By Disease Indication (2024-2032) ($MN)
  • Table 25 Global Telomere Gene Therapy Market Outlook, By Idiopathic Pulmonary Fibrosis (2024-2032) ($MN)
  • Table 26 Global Telomere Gene Therapy Market Outlook, By Aplastic Anemia (2024-2032) ($MN)
  • Table 27 Global Telomere Gene Therapy Market Outlook, By Cancer Subtypes (2024-2032) ($MN)
  • Table 28 Global Telomere Gene Therapy Market Outlook, By Rare Telomere Disorders (2024-2032) ($MN)
  • Table 29 Global Telomere Gene Therapy Market Outlook, By Application (2024-2032) ($MN)
  • Table 30 Global Telomere Gene Therapy Market Outlook, By Anti-Aging & Longevity (2024-2032) ($MN)
  • Table 31 Global Telomere Gene Therapy Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 32 Global Telomere Gene Therapy Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 33 Global Telomere Gene Therapy Market Outlook, By Regenerative Medicine (2024-2032) ($MN)
  • Table 34 Global Telomere Gene Therapy Market Outlook, By End User (2024-2032) ($MN)
  • Table 35 Global Telomere Gene Therapy Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 36 Global Telomere Gene Therapy Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 37 Global Telomere Gene Therapy Market Outlook, By Biotech & Pharmaceutical Companies (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.